https://thehill.com/policy/healthcare/488807-fda-authorizes-first-rapid-point-of-care-coronavirus-test Food and Drug Administration (FDA) has approved the first coronavirus diagnostic test that can be conducted entirely at the point of care. The test from California-based Cepheid will deliver results in about 45 minutes – much faster than current tests that require a sample to be sent to a centralized lab, where results can take days. The test has been designed to operate on any of Cepheid's more than 23,000 automated GeneXpert Systems worldwide, of which 5,000 are in the U.S., the company said. The systems are already being used to test for conditions like HIV or tuberculosis. The systems do not require users to have specialty training to perform testing, and are capable of running around the clock. "An accurate test delivered close to the patient can be transformative — and help alleviate the pressure" that the COVID-19 outbreak has put on health facilities, David Persing, Cepheid's chief medical and technology officer, said in a statement. "People in general are frustrated with the turnaround time. They don't know their status until days later. Knowing your status quickly ... this will allow much better decision making" and help doctors decide which treatment is best, Persing said in a video on the company's website. The test initially will be used primarily by hospitals, the company said, but FDA's "emergency use authorization" covers all “patient care settings,” including doctors’ offices. The test will begin shipping next week.
https://thehill.com/policy/healthcare/488807-fda-authorizes-first-rapid-point-of-care-coronavirus-test Food and Drug Administration (FDA) has approved the first coronavirus diagnostic test that can be conducted entirely at the point of care. The test from California-based Cepheid will deliver results in about 45 minutes – much faster than current tests that require a sample to be sent to a centralized lab, where results can take days. The test has been designed to operate on any of Cepheid's more than 23,000 automated GeneXpert Systems worldwide, of which 5,000 are in the U.S., the company said. The systems are already being used to test for conditions like HIV or tuberculosis. The systems do not require users to have specialty training to perform testing, and are capable of running around the clock. "An accurate test delivered close to the patient can be transformative — and help alleviate the pressure" that the COVID-19 outbreak has put on health facilities, David Persing, Cepheid's chief medical and technology officer, said in a statement. "People in general are frustrated with the turnaround time. They don't know their status until days later. Knowing your status quickly ... this will allow much better decision making" and help doctors decide which treatment is best, Persing said in a video on the company's website. The test initially will be used primarily by hospitals, the company said, but FDA's "emergency use authorization" covers all “patient care settings,” including doctors’ offices. The test will begin shipping next week.
https://thehill.com/policy/healthcare/488807-fda-authorizes-first-rapid-point-of-care-coronavirus-test
Food and Drug Administration (FDA) has approved the first coronavirus diagnostic test that can be conducted entirely at the point of care.
The test from California-based Cepheid will deliver results in about 45 minutes – much faster than current tests that require a sample to be sent to a centralized lab, where results can take days.
The test has been designed to operate on any of Cepheid's more than 23,000 automated GeneXpert Systems worldwide, of which 5,000 are in the U.S., the company said. The systems are already being used to test for conditions like HIV or tuberculosis.
The systems do not require users to have specialty training to perform testing, and are capable of running around the clock.
"An accurate test delivered close to the patient can be transformative — and help alleviate the pressure" that the COVID-19 outbreak has put on health facilities, David Persing, Cepheid's chief medical and technology officer, said in a statement.
"People in general are frustrated with the turnaround time. They don't know their status until days later. Knowing your status quickly ... this will allow much better decision making" and help doctors decide which treatment is best, Persing said in a video on the company's website.
The test initially will be used primarily by hospitals, the company said, but FDA's "emergency use authorization" covers all “patient care settings,” including doctors’ offices.
The test will begin shipping next week.
当时我记得说的的是，
下周一，可以测100万，紧接着200万，然后400万
那让人兴奋得股市都涨了10%
想起来对吃瓜群众说下周一见，仿佛是很久以前的事了
你这种人也太难伺候了
那是因为再紧急 还是要过周末 病毒可不过周末
无论如何总是好消息 很多人一开始就在等这个可以就地检查的 就像flu test一样
Re, agree
已经派军用飞机从意大利购医疗公司运回800,000 swabs，接下来还要飞几趟，1.5million/week的供应。
总会解决问题的
Roche的今天就已经到美国Midwest大农村小县城的医院了，每天可以测600个，本来说要月底才到的。
所以那个小老头Tony Fauci才说，关键是可以自己取样的测试，正在开发中，看样子也快了。
是啊。还是看华人网上不给测的帖子真实的多